New Injectable Agents for the Treatment of Type 2 Diabetes Part 1 – Injectable Insulins - 18/06/18
, AhYoung Byun, Pharm.D a, Amanda Howard-Thompson, Pharm.D, BCPS, CDE a, bRhonda M. Cooper-Rettoff, PharmD, MS, Pharmacology Series Editor
Abstract |
The United States Food and Drug Administration has recently approved several new insulin products and new formulations of existing insulin products. These new products may provide advantages over older products, such as a lower risk of nocturnal hypoglycemia and ease of dosing; however, they are costly. The first of 2 articles in a series, this review will describe the potential advantages and disadvantages of these new insulin products.
Le texte complet de cet article est disponible en PDF.Keywords : Concentrated insulin, Insulin, Insulin analog, Type 2 diabetes
Plan
| Funding: None. |
|
| Conflicts of Interest: None. |
|
| Authorship: All authors had access to the data and a role in writing this manuscript. |
Vol 131 - N° 7
P. 752-754 - juillet 2018 Retour au numéro
Article précédent
- Management of Common Benign Anorectal Disease: What All Physicians Need to Know
- David Parés, Herand Abcarian
- Cannabinoids in Patients with Nausea and Vomiting Associated with Malignancy and Its Treatments
- Jose M. Garcia, Tatyana A. Shamliyan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?